In a nutshell The study aimed to investigate the safety and effectiveness of immunotherapy drug tebentafusp in previously untreated advanced uveal melanoma. The study showed that tebentafusp is effective and improved the overall survival in patients with uveal melanoma. Some background Melanoma is an aggressive kind of skin cancer. Uveal melanoma...Read More
Melanoma Posts on Medivizor
In a nutshell This study is aimed to evaluate the risk of infection for patients who are treated with immune checkpoint inhibitors (ICI) for solid tumors. The study concluded that in frail patients, ICI therapy alone is safer compared to chemotherapy (CT). Some background Immunotherapy is a type of cancer treatment that makes use of the...Read More
Does early use of high-dose glucocorticoids affect survival in patients with advanced melanoma treated with anti-PD-1 therapy?
In a nutshell This study evaluated the use of high-dose glucocorticoids (GCs) and their impact on the survival outcomes during anti-PD-1 therapy for the treatment of patients with advanced melanoma. The data showed that early high-dose GC use was associated with poorer outcomes after the onset of immune-related side effects. Some background...Read More
In a nutshell This study looked at the skin-related side effects of immune checkpoint inhibitors in the treatment of melanoma. It found that the most common side effects were mild-to-moderate itching, rash, and vitiligo (loss of skin pigment). Some background Immune checkpoint inhibitors (ICIs) are a type of immune therapy used to...Read More
Evaluating the effectiveness and safety of triple combination therapy with immunotherapy and targeted therapy for patients with advanced-stage melanoma.
In a nutshell This study evaluated the effectiveness and safety of triple combination therapy with immune and targeted therapies in patients with stage III-IV melanoma. The data showed that triple combination therapy was associated with increased survival benefits with manageable side effects for these patients. Some background Melanoma is an...Read More
Is surgery of metastases effective after failure of modern whole-body treatments in patients with advanced melanoma?
In a nutshell This study looked at the use of surgery for spread disease (metastases) in patients with advanced melanoma when other whole-body treatments had failed. It found that surgical removal of metastases improved the outcomes of these patients. Some background Advanced melanoma can spread to many places in the body. It is usually...Read More
In a nutshell This study looked at the use of robotic-assisted CyberKnife radiosurgery to treat iris melanomas. It found that this is a promising treatment for iris melanoma. Some background Melanomas are the most common tumors of the eye. Eye melanomas usually occur at the back of the eye, but sometimes they affect the iris (the colored...Read More
What is the effective dose of ipilimumab combined with standard dose of pembrolizumab in patients with advanced melanoma?
In a nutshell The study aimed to evaluate the effectiveness and safety of combining standard-dose pembrolizumab (PEM; Keytruda) with two different doses of ipilimumab (IPI; Yervoy) in patients with advanced melanoma. The study concluded that 200 mg PEM plus 50 mg of IPI showed good effectiveness and reduced toxicity compared to 100 mg...Read More
Evaluating the long-term outcomes of cobimetinib plus vemurafenib in patients with BRAF-mutated advanced melanoma.
In a nutshell This study reported the long-term effectiveness and safety of the combined treatment of vemurafenib (Zelboraf) and cobimetinib (Cotellic) in patients with previously untreated BRAF-mutated advanced melanoma. The data showed that the combination was safe and effective over the long term. Some background Melanoma is an aggressive...Read More
Is a skin rash associated with the treatment response to vemurafenib and cobimetinib in patients with advanced melanoma?
In a nutshell The study aimed to investigate the frequency and severity of skin rash-like symptoms known as exanthema and its relationship with treatment outcome with vemurafenib (Zelboraf) alone or vemurafenib combined with cobimetinib (Cotellic) in patients with advanced melanoma. The study showed that the appearance of exanthema within 6 weeks of...Read More
In a nutshell This study evaluated if there were any clinical indicators to identify which patients with advanced melanoma would benefit from immune checkpoint blocker (ICB) therapy. The data showed that blood LDH levels, the extent of disease, number of white blood cells, and immune-related side effects were all associated with better...Read More
Is pembrolizumab plus ipilimumab combination therapy safe and effective for the treatment of advanced melanoma after failure of anti-PD-1/L1 therapy?
In a nutshell This study aimed to investigate the effectiveness and safety of combining pembrolizumab (PEM; Keytruda)) and ipilimumab (IPI; Yervoy) for the treatment of advanced-stage melanoma in patients that have progressed after previous PD-1/L1 therapy. The study concluded that this combination was well tolerated and improved the...Read More